Neues zur Neuroborreliose

Zusammenfassung

Borrelia burgdorferi verursacht eine Vielzahl klinisch gut charakterisierter Krankheitsbilder, die verschiedene Organsysteme betreffen. Im neurologischen Fachgebiet stellt die akute frische Neuroborreliose kein Problem dar; sie ist klinisch und liquoranalytisch meist sicher zu diagnostizieren und gut zu therapieren. In den letzten Jahren sind jedoch vermehrt Berichte in der Laienpresse und medizinischen Literatur erschienen, dass bei Patienten nach durchgemachter Borreliose relativ unspezifische Symptome auftreten können, die einer chronischen Form der Neuroborreliose entsprechen sollen. In diesem Artikel werden einige neuere Beiträge zu dieser Diskussion zusammengefasst sowie neue Erkenntnisse zur Postexpositionsprophylaxe und Borrelien-Impfung dargestellt.

Summary

Lyme-disease comprises a multitude of clinically well characterized manifestations affecting different organ systems. For a neurologist, the acute neuroborreliosis is normally easy to handle, due to clear-cut clinical and CSF-findings. However, reports have appeared in both the lay press and the medical literature of persons who were diagnosed as having Lyme disease and subsequently developed non-specific symptoms attributed to so-called chronic neuroborreliosis. In this article, some recent contributions to this discussion as well as latest developments concerning early chemoprophylaxis and vaccination are reported.

Schlüsselwörter

Chronische Neuroborreliose - Langzeit-Antibiotikabehandlung - Postexpositionsprophylaxe - Impfung

Keywords

Chronic neuroborreliosis - long-term antibiotic treatment - chemoprophylaxis - vaccination

• Literatur

• 1 Agre F, Schwartz R. The value of early treatment of deer tick bites for the prevention of Lyme disease. Am J Dis Child 1993; 147: 945-7.
• 2 Asbrink E, Hovmark A. Early and late cutaneous manifestations of Ixodes-borne borreliosis (erythema migrans borreliosis, Lyme borreliosis). Ann NY Acad Sci 1988; 539: 4-15.
• 3 Berglund J, Stjernberg L, Ornstein K. et al. 5-y follow-up study of patients with neuroborreliosis. Scand J Infect Dis 2002; 34: 421-5.
• 4 Christen HJ. Lyme neuroborreliosis in children. Ann Med 1996; 28: 235-40.
• 5 Costello CM, Steere AC, Pinkerton RE, Feder Jr HM. A prospective study of tick bites in an endemic area for Lyme disease. J Infect Dis 1989; 159: 136-9.
• 6 Gross DM, Forsthuber T, Tary-Lehmann M. et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science 1998; 281: 703-6.
• 7 Halperin JJ, Little BW, Coyle PK, Dattwyler RJ. Lyme disease: cause of a treatable peripheral neuropathy. Neurology 1987; 37: 1700-6.
• 8 Halperin JJ, Luft BJ, Anand AK. et al. Lyme neuroborreliosis: central nervous system manifestations. Neurology 1989; 39: 753-9.
• 9 Halperin JJ, Luft BJ, Volkman DJ, Dattwyler RJ. Lyme neuroborreliosis – peripheral nervous system manifestations. Brain 1990; 113: 1207-21.
• 10 Hauser U, Lehnert G, Wilske B. Validity of interpretation criteria for standardized western blots (immunoblots) for the serodiagnosis of Lyme borreliosis based on sera collected throughout europe. J Clin Microbiol 1999; 37: 2241-7.
• 11 Hopf HC. Acrodermatitis chronica atrophicans (Herxheimer) und Nervensystem. Monogr Neurol Psychiatr, Heft 114. Berlin: Springer Verlag; 1966
• 12 Kaiser R. Neuroborreliosis. J Neurol 1998; 245: 247-55.
• 13 Kalish RA, McHugh G, Granquist J. et al. Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001; 33: 780-5.
• 14 Kalish RA, Kaplan RF, Taylor E. et al. Evaluation of study patients with Lyme disease, 10-20 year follow-up. J Infect Dis 2001; 183: 453-60.
• 15 Kindstrand E, Nilsson BY, Hovmark A. et al. Polyneuropathy in late Lyme borreliosis – a clinical, neurophysiological and morphological description. Acta Neurol Scand 2000; 101: 47-52.
• 16 Klempner MS, Hu LT, Evans J. et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 85-92.
• 17 Kristoferitsch W, Sluga E, Graf M. et al. Neuropathy associated with acrodermatitis atrophicans. Ann NY Acad Sci 1987; 539: 35-45.
• 18 Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med 1990; 323: 1438-44.
• 19 Logigian EL, Kaplan RF, Steere AC. Successful treatment of Lyme encephalopathy with intravenous ceftriaxone. J Infect Dis 1999; 180: 377-83.
• 20 Logigian EL, Steere AC. Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease. Neurology 1992; 42: 303-11.
• 21 Nadelman RB, Nowakowski J, Fish D. et al. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite. N Engl J Med 2001; 345: 79-84.
• 22 Oehme R. Stammdifferenzierung von Borrelia burgdorferi: Epidemiologische Grundlage für die Entwicklung eines Impfstoffs. Landesgesundheitsamt Baden-Württemberg/Jahresbericht 1999; 53-4.
• 23 Oschmann P, Dorndorf W, Hornig C. et al. Stages and syndromes in neuroborreliosis. J Neurol 1998; 245: 262-72.
• 24 Rosé CD, Fawcett PT, Gibney KM. Arthritis following recombinant outer surface protein A vaccination for Lyme disease. J Rheumatol 2001; 28: 2555-7.
• 25 Schutzer SE, Natelson BH. Absence of Borrelia burgdorferi-specific immune complexes in chronic fatigue syndrome. Neurology 1999; 53: 1340-1.
• 26 Seltzer EG, Gerber MA, Cartter ML. et al. Long-term outcome of persons with Lyme disease. JAMA 2000; 283: 609-16.
• 27 Shadick NA, Phillips CB, Sangha O. et al. Musculoskeletal and neurologic outcomes in patients with previously treated Lyme disease. Ann Intern Med 1999; 131: 919-26.
• 28 Shapiro ED, Gerber MA, Holabird ND. et al. A controlled trial of antimicrobial prophylaxis for Lyme disease after deer-tick bites. N Engl J Med 1992; 327: 1769-73.
• 29 Sigal LH, Zahradnik JM, Lavin P. et al. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998; 339: 216-22.
• 30 Steere AC, Bartenhagen NH, Craft JE. et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99: 76-82.
• 31 Steere AC, Sikand VK, Meurice F. et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl J Med 1998; 339: 209-15.
• 32 Steere AC. Lyme disease. N Engl J Med 2001; 345: 115-25.
• 33 Vrethem M, Hellblom L, Widlund M. et al. Chronic symptoms are common in patients with neuroborreliosis – a questionnaire followup study. Acta Neurol Scand 2002; 106: 205-8.
• 34 Warshafsky S, Nowakowski J, Nadelman RB. et al. Efficacy of antibiotic prophylaxis for prevention of Lyme disease. J Gen Intern Med 1996; 11: 329-33.
• 35 Wilske B, Zöller L, Brade V. et al. MiQ-12 Lyme Borreliose. In: Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. Mauch H, Lütticken R, Gatermann S. eds München: Urban & Fischer; 2000: 1-59.
• 36 Wilske B. Microbiological diagnosis in Lyme borreliosis. Int J Med Microbiol 2002; 291 (Suppl. 33) 114-9.